Members are listed alphabetically.
Click on thumbnail to view profile.
Return to ICT Main Page
We are
committed to continuing investment in oncology research to
discover and develop more targeted and less toxic therapies than
are currently available for a broad range of cancers. We have
several different classes of compounds in various stages of
clinical development. These approaches address multiple phases
of cancer progression, including angiogenesis (new blood vessel
formation), signal transduction and programmed cell death
(apoptosis).
Advaxis is a discovery stage biotech
company developing bioengineered Listeria
monocytogenes for use as a live cancer vaccine vector.
Listeria is safe to use as a live
vaccine vector. As an environmental pathogen found in our food
supply and routinely ingested, it is a pathogen with which we
have an immune relationship. It is not laterally transmissible,
and other than the immunosurpressed and 3rd trimester
pregnant or nursing women Listeria is safe in most
people,. In the event of a problem Listeria infection
can be sterilized rapidly with a low dose of a variety of common
antibiotics.
Listeria is a pathogen that infects
the immune system and offers an unusual ability to manipulate a
number of important immune mechanisms in a simultaneous and
integrated fashion, including: stimulation of effector cells
(CD4+, CD8+, DC, macrophages, etc),
stimulation of many immune mediators (Th-1 cytokines, chemokines,
co-stimulatory molecules, GM-CSF and others), maturation of
immature immune cells and the stimulation of monopoesis, as well
as the ability to remove inhibitory influences on the immune
response (Tregs, immature myeloid cells). By infecting Antigen
Presenting Cells (APC) Listeria vaccines have the ability
to redirect a whole body immune response and focus it on which
ever tumor specific antigen is bioengineered into the
construct. By using a proprietary fusion protein in which the
microbe is engineered to secrete a tumor specific antigen fused
to a Listeria protein dramatic increases in efficacy have
been observed.
The first live Listeria vaccine in
the clinic is Lovaxin C (Lm-LLO-E7) directed against the HPV-16
E7 antigen presumed to cause most of the cervical cancer seen in
the US. In Phase I only a flu-like syndrome was associated with
Lovaxin C administration. Various studies to test Lovaxin C in
early stage disease, adjuvant models, and other protocols are
planned.
Advaxis is pleased to be associated with
GOG in the development of this agent.
http://www.advaxis.com
AltheaDx provides a start-to-finish suite of
services focused on molecular biomarker discovery, assay
development, assay validation and prospective/retrospective
clinical trial testing in support of companion diagnostic
development and commercialization. At the core of our services
is a comprehensive set of gene expression and genotyping
analysis capabilities for both pre-clinical and clinical
applications utilizing state of the art genomics tools including
real-time PCR, microarray technologies and next-generation
sequencing. All of our services can be run under non-GLP, full
GLP compliance and CLIA.
AltheaDx
is currently developing unique diagnostic assays, including
Oncoscore Ovarian in a collaborative effort with
Compendia Bioscience. The OncoScore™ diagnostic assays are
based on the premise that gene expression patterns in cancer are
capable of stratifying patients and that this molecular
heterogeneity of cancer can be reduced to small number of core
gene expression “modules” of biological function which
correspond to cell lineage, pathway activation, de-regulation of
a cellular process, genomic alterations or tumor
microenvironment.
http://www.altheadx.com
Amgen is a global biotechnology company that discovers, develops, manufactures
and markets important human therapeutics based on advances in cellular and
molecular biology.
http://www.amgen.com
Astellas was formed in 2005 from the
historic merger of Yamanouchi and Fujisawa, two of Japan’s
leading pharmaceutical companies. Building on this combined
heritage, we at Astellas are dedicated to changing tomorrow for
people around the world by developing innovative and reliable
therapies for hard-to-treat diseases and conditions.
By focusing our research and development effort on innovative
solutions, and by collaborating with dynamic partners, Astellas
is increasingly committed to oncology therapeutics. Our goal of
developing treatments for today’s medical challenges depends on
partnerships with healthcare providers and patients. We invite
you to become a partner with Astellas Oncology and join us in
our vision for changing tomorrow in cancer care.
Boehringer Ingelheim
is building on its long-standing research and development
capabilities and expertise in several other disease areas (e.g.,
respiratory, cardiovascular, virology and metabolic disorders),
and the strong scientific foundation provided by its research
and development centers worldwide. Several years ago,
Boehringer Ingelheim started to engage in cancer research in
response to the unmet medical needs of patients with cancer and
has made advances in understanding cancer biology. With its
cancer research and development program, Boehringer Ingelheim is
committed to discovering and developing innovative cancer
treatments that provide high therapeutic value for patients and
healthcare providers. Building on breakthrough science to
develop targeted therapies, small molecules and biologics,
Boehringer Ingelheim is focusing its research on areas of unmet
medical need, including lung, breast, ovarian, colorectal and
prostate cancers, as well as lymphomas and leukemias.
Boehringer Ingelheim
employs more than 200 scientists in its cancer research facility
at the Boehringer Ingelheim Austria Regional Centre in Vienna to
discover new cancer medicines. Promising drug candidates are
developed by the non-clinical and clinical development
organization of Boehringer Ingelheim, representing a team of
nearly 400 professionals working in oncology. Their efforts,
combined with those of leading experts in cancer research and
medicine at universities and cancer hospitals, are focused on
developing a range of next-generation therapeutics to combat
cancer. Compounds under investigation in oncology focus on
three areas: angiogenesis inhibitors, signal transduction
inhibitors and cell-cycle kinase inhibitors.
Bristol-Myers Squibb is the world leader in providing life-saving
and life-extending therapies for people with cancer. All of the
company's considerable resources and expertise in oncology are
marshaled toward the single goal of providing safer and more
effective anticancer medicines. The mission of Bristol-Myers
Squibb Oncology is to extend and enhance the lives of people
living with cancer.
http://www.BMS.com
Celgene Corporation (Nasdaq:CELG)
is a global biopharmaceutical company that is helping
healthcare providers turn incurable cancers and other
serious conditions into chronic, manageable diseases through
innovative therapies. This dedication to medical progress
goes hand-in-hand with our industry-leading patient support
and access programs. Together, these aspects form the core
of our commitment to patients worldwide.
www.celgene.com
CTI is committed to developing, acquiring, and commercializing innovative
treatments for cancer. In its pursuit of making cancer more treatable, the
Company is developing a diversified portfolio of oncology drugs. Our research
and in-licensing activities are concentrated on identifying new, less toxic,
and more effective ways to treat cancer.
CTI's product pipeline includes one marketed drug, TRISENOX, and several investigational
drugs that may address the therapeutic limitations of conventional cancer therapies.
Our most advanced investigational drug, XYOTAX (polyglutamate paclitaxel), is currently
in Phase III for non-small-cell lung and ovarian cancers. Together, these drug candidates
represent our progress in making cancer a more treatable disease.
http://www.cticseattle.com
EGEN, Inc. is
a privately held biopharmaceutical company specialized in
nucleic acid (DNA, RNAi) therapeutics and delivery via
proprietary TheraPlas™ and TheraSilence™ technologies.
EGEN is
developing safe and efficient delivery systems to be used to
create products for treatment of human diseases with a focus
on cancer. The delivery systems function by protecting the
therapeutic cargo from degradation, promoting uptake by the
target cells and facilitating intracellular trafficking.
Unique chemistry and formulation strategies, designed to
overcome delivery barriers, differ substantially from other
approaches and are the distinguishing characteristics of
EGEN’s proprietary technology
EGEN’s lead product (EGEN-001) is an Immunotherapeutic
(IL-12 plasmid & TheraPlas™ delivery polymer) that has
successfully completed Phase I and Phase IA ovarian cancer
trials with favorable clinical trials response.
EGEN-001 was listed in “Top 100 Investigational Drugs” by
R&D Directions and selected to Windhover’s “Top 10 Oncology
Drugs Available for Partnering”.
Endocyte is working to
improve the diagnostic and treatment options for many types of
cancer and inflammatory disease using a new proprietary drug
guidance system (DGS). Endocyte DGS technology is designed to
target a wide variety of drugs to diseased cells while avoiding
healthy cells. Endocyte’s advanced DGS technology combines drugs
with ligands that efficiently bind to receptors overexpressed on
diseased cells. By targeting cell-surface receptors, Endocyte’s
DGS delivers potent anti-cancer agents directly to cancer cells
while avoiding delivery to healthy cells.
Genentech is a leading biotechnology company that
discovers, develops, manufactures and commercializes biotherapeutics for
significant
unmet medical needs. Genentech manufactures and commercializes several major
oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.
http://www.genentech.com
GlaxoSmithKline
is a world leading research based pharmaceutical company with a
powerful combination of skills and resources that provides a
platform for delivery of strong growth in today’s rapidly
changing environment. GlaxoSmithKline’s mission is to improve
the quality of human life by enabling people to do more, feel
better and live longer.
GlaxoSmithKline
also has leadership in four major therapeutic areas – anti-infectives,
central nervous system, respiratory and
gastro-intestinal/metabolic. In addition, GlaxoSmithKline is a
leader in the important area of vaccines and has a growing
portfolio of oncology products, including Hycamtin (topotecan
HCL) for relapsed ovarian cancer and Navelbine (vinorelbine
tartrate). GlaxoSmithKline Oncology also has a dedicated sales
force committed to women’s cancers, including oncology medical
scientists and oncology nurse educators.
http://www.glaxosmithkline.com
Eli Lilly and Company is a leading innovation-driven
corporation and is developing a growing portfolio of best-in-class
pharmaceutical products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly provides
answers – through medicines and information – for some of the world’s most
urgent medical needs.
Lilly Oncology is committed to providing comprehensive healthcare
solutions – answers that matter – for oncologists and cancer patients around
the world through the discovery and development of breakthrough cancer medicines.
http://www.lilly.com
Mira Dx is an emerging molecular
diagnostics company dedicated to the assessment of risk and
improvement of therapeutic efficacy in women’s health. The
company’s mission is to become a leader in women’s personalized
medicine by supplying patients and their doctors with high
impact genetic risk and therapeutic response information. Mira
Dx’s science platform is based on the novel science of microRNA
genetics. The company is supplying its proprietary test through
a CLIA certified laboratory.
“You need to know”
Morphotek®, Inc., a subsidiary of Eisai
Corporation of North America, is a biopharmaceutical company
specializing in the development of protein and antibody products
through the use of a novel and proprietary gene evolution
technology. The technology has been successfully applied to a
broad variety of cell lined and organisms to yield genetically
diverse offspring that are suitable for pharmaceutical product
development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and
improved output traits for commercial applications. The company
is currently focusing its platform on the development and
manufacturing of therapeutic antibodies for the treatment of
cancer, inflammation and infectious disease. For more information, please visit
http://www.morphotek.com
Novartis Oncology is
dedicated to innovative approaches, practical solutions and
valuable medical therapies that satisfy the current and emerging
needs of the Oncology community. Current marketed products in
oncology are Gleevec™, Femara™, Zometa™, and Sandostatin™
http://www.novartisoncology.com
OvaGene
Oncology
is a molecular diagnostics company, located in Orange County
California, dedicated to improving cancer care and outcomes for
gynecologic cancer patients through the development of novel
gene-based assays. The company plans to offer proprietary and
non-proprietary molecular diagnostic assays to assist physicians
in the prognosis of gynecologic cancers as well as therapy
selection, including radiation and chemotherapy. Please visit
our website at
www.ovagene.com for
more information about our company.
Pfizer is a research-based global pharmaceutical company dedicated to helping people live longer,
healthier lives. It invests more than $2 billion annually in research, searching for treatments and cures
for cancer, osteoporosis, diabetes, Alzheimer's disease, arthritis, heart disease, sexual dysfunction, and a
wide variety of other diseases. Pfizer is also a leader in animal health, offering medicines for companion and
farm animals, and in consumer health care products.
http://www.pfizer.com
Precision
Therapeutics, a life-science company based in Pittsburgh,
Pennsylvania, is committed to improving outcomes of cancer
patients. As leaders in the science of individualizing cancer
therapy through the use of a proprietary and unique live-tissue
platform, Precision develops novel markers to help guide
treatment decisions based on the biological processes of each
individual’s cancer.
Precision’s
state of the art bioinformatics combined with the analysis of
the live molecular, proteomic and genomic activity of each
patient’s cancer offer an innovative foundation for further
development and commercialization of novel predictive markers
for cancer therapy. Precision’s first commercial test, ChemoFx®,
is a proprietary drug response marker which measures an
individual’s malignant tumor response to a range of standard
therapeutic alternatives under consideration by a physician.
http://www.ptilabs.com
Regeneron Pharmaceuticals, Inc.
is a fully integrated
biopharmaceutical company that discovers, develops, and
commercializes medicines for the treatment of serious medical
conditions. Regeneron has therapeutic candidates for the
potential treatment of cancer, eye diseases, and inflammatory
diseases and has preclinical programs in other diseases and
disorders.
New Drug
Development Technology Platforms
Regeneron has developed the VelociSuite of technologies,
comprising VelociGene®, VelociMouse™,
VelocImmune®, and VelociMab™, which increases the
efficiency and decreases the time involved in progressing from
early discovery efforts through drug candidate generation.
Together, these technologies allow Regeneron scientists to
determine the best targets for therapeutic intervention, and
then rapidly generate high-quality, fully human antibodies as
drug candidates addressing these targets.
www.regeneron.com
The
sanofi-aventis Group is the world’s 3rd largest pharmaceutical
company, ranking number 1 in Europe. Backed by a world-class
R&D organization, sanofi-aventis is developing leading positions
in seven major therapeutic areas: cardiovascular disease,
thrombosis, oncology, diabetes, central nervous system,
internal medicine, vaccines. The sanofi-aventis Group is listed
in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). Please
visit sanofi-aventis at
www.sanofi-aventis.com.
www.seprafilm.com
VentiRx Pharmaceuticals, Inc. is a clinical stage oncology
biopharmaceutical company committed to the development and
commercialization of innovative
immunotherapeutics. The company is the leader in the
development of novel small molecules targeting Toll-Like
Receptor 8 (TLR8). The lead candidate, VTX-2337 is a TLR8
agonist with a broad development program underway in multiple
oncology indications and treatment combinations. The company’s
pipeline consists of a proprietary library of small molecule
TLR8 agonists and antagonists representing additional
opportunities in respiratory and autoimmune diseases.
www.ventirx.com
